review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Ole Kirk | Q102213445 |
Amanda Mocroft | Q47006497 | ||
Jürgen Rockstroh | Q47006499 | ||
Daniel Grint | Q56334582 | ||
Jens Lundgren | Q42325404 | ||
P2093 | author name string | Lars Peters | |
P2860 | cites work | Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection | Q57877746 |
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? | Q81473082 | ||
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 | ||
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? | Q51070641 | ||
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C | Q57877639 | ||
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | Q28274666 | ||
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. | Q33648600 | ||
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C | Q33955516 | ||
Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients | Q34749550 | ||
The rapid evolution of treatment strategies for hepatitis C. | Q38204657 | ||
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection | Q39526550 | ||
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study | Q39759946 | ||
Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? | Q41332840 | ||
High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance | Q42215928 | ||
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis | Q42230942 | ||
Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. | Q42980077 | ||
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe | Q42981324 | ||
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients | Q42982110 | ||
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression | Q42986831 | ||
Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection | Q42988737 | ||
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy | Q42990589 | ||
Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection | Q43034920 | ||
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial | Q43040301 | ||
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? | Q45422165 | ||
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy | Q45424761 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Argentina | Q414 |
Israel | Q801 | ||
hepatitis C | Q154869 | ||
infection | Q166231 | ||
human immunodeficiency virus infectious disease | Q18556697 | ||
RNA virus infectious disease | Q18967413 | ||
Retroviridae infectious disease | Q19000689 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | S13 | |
P577 | publication date | 2014-09-19 | |
P1433 | published in | BMC Infectious Diseases | Q15759919 |
P1476 | title | HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective | |
P478 | volume | 14 Suppl 6 |
Q61958644 | Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission |
Q45255359 | Editorial: direct-acting anti-virals - not the be-all and end-all in HIV/HCV co-infection |
Q40481513 | Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. |
Q38950820 | European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements |
Q92518090 | Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey |
Q55411140 | Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland. |
Q40671938 | Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. |
Q90644707 | Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model |
Q40355278 | Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna |
Search more.